icotec’s KONG®-TL and the KONG®-C vertebral body replacements received FDA 510(k) clearance in the U.S. and CE Mark approval in Europe.
The devices are made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.
The 360° Ti-iT pure titanium coating, featuring an optimized osseoconductive structure, is designed to support rapid engraftment of bone onto the implant. BlackArmor Carbon/PEEK implant material enables artefact-free imaging and aids in planning, application and follow-up care of radiotherapy for patients with tumors.
“With the imminent market launch of the KONG-TL/C vertebral body replacement systems in Europe and the U.S., we have made significant strides toward achieving this target [of establishing a complete product portfolio that provides patients with improved therapy options],” said Roger Stadler, CEO.
icotec's KONG®-TL and the KONG®-C vertebral body replacements received FDA 510(k) clearance in the U.S. and CE Mark approval in Europe.
The devices are made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.
The 360° Ti-iT pure titanium coating, featuring an optimized osseoconductive...
icotec’s KONG®-TL and the KONG®-C vertebral body replacements received FDA 510(k) clearance in the U.S. and CE Mark approval in Europe.
The devices are made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.
The 360° Ti-iT pure titanium coating, featuring an optimized osseoconductive structure, is designed to support rapid engraftment of bone onto the implant. BlackArmor Carbon/PEEK implant material enables artefact-free imaging and aids in planning, application and follow-up care of radiotherapy for patients with tumors.
“With the imminent market launch of the KONG-TL/C vertebral body replacement systems in Europe and the U.S., we have made significant strides toward achieving this target [of establishing a complete product portfolio that provides patients with improved therapy options],” said Roger Stadler, CEO.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
